Compound Radar

Surgery Partners, Inc. (SGRY) Stock Analysis

Price $13.96
Market cap $1.83B
Next earnings Nov 9, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

50
50/100 Speculative
  • Financial Health 50
  • Profitability 50
  • Business Quality 60
  • Balance Sheet 30
  • Cash Flow 60

Why this rating?

Health 50/100 — Speculative

Strongest Business Quality 60/100
Softest Balance Sheet 30/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Surgery Partners, Inc. (SGRY) is a Medical Care Facilities company in the Healthcare sector. Compound Radar rates Surgery Partners, Inc. 50/100 (Speculative) due to solid business quality, steady revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Moderate
  • Balance Sheet Stretched
  • Valuation Fair

Financial highlights

Valuation

  • Forward P/E 22.26
  • EV/Revenue 2.23

Profitability

  • Revenue Growth 2.7%
  • Gross Margin 22.5%
  • Operating Margin 13.7%
  • Net Margin -2.6%
  • ROE 2.3%

Financial strength

  • Cash $216.70M
  • Debt $4.07B
  • Net Cash $-3.85B
  • Free Cash Flow $195.60M
  • Current Ratio 1.95

Similar companies

Peers in Medical Care Facilities, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Care Facilities →

FAQ

How Compound Radar scores and tracks Surgery Partners, Inc. (SGRY).

View Methodology & FAQ →